Signalpoint

← Full daily brief

Mass Tort brief

Corporate Shields and Settlement Hurdles

Teva races against critical US litigation deadlines while Israel's Supreme Court moves to penalize weak class actions.

Signalpoint TeamBrief

Mass Tort

Tel Aviv-listed Teva is settling legacy US antitrust claims while aggressively reviving patent battles — clearing liabilities to protect its critical generic launch pipeline.

BackgroundGeneric drug giant Teva relies heavily on its US commercial pipeline to fuel growth and service its massive debt. Resolving multi-million-dollar legacy antitrust and product liability claims is critical to protecting the company's upcoming product launches.

Points
  1. The $35M QVAR settlement resolves long-running claims that Teva blocked generic competitors, potentially clearing the path for cheaper alternative respiratory treatments in the US market.
  2. Teva and its generic peers pushed back their Metformin contamination class action settlement deadline to August 5, delaying the resolution of consumer claims over NDMA impurities.
  3. The Seventh Circuit's ruling revives Teva's lawsuit alleging Eli Lilly used anti-competitive tactics, which could yield substantial damages if Teva proves Lilly delayed its generic Forteo launch.
SourcesRefund Advocacy: Teva QVAR Inhaler Antitrust Settlement Class Action (opens in new tab)VitalLaw: GENERIC DRUGS—7th Cir.: Teva's lawsuit over osteoporosis drug settlement against Eli Lilly revived on appeal (opens in new tab)Claim Depot: Teva, Granules, Heritage $5.55M Metformin Settlements (opens in new tab)

Mass Tort

The Israeli Supreme Court is preparing to penalize weak class actions with heavy legal costs — handing local corporate defendants a vital shield against frivolous product liability claims.

BackgroundIsrael has experienced an explosion of consumer class actions over the past two decades, aided by low filing fees. Business groups have long lobbied for reform, arguing that defending weak product liability cases carries disproportionate financial burdens.

Points
  1. The Supreme Court declined to impose heavy costs on the Renault plaintiffs but stated clearly that future rulings will reflect realistic legal fees.
  2. Corporate defendants expect the judicial shift to provide a strong defense against speculative filings, lowering their long-term litigation exposure in Israel.
  3. Local legal experts predict the warning will deter plaintiff attorneys from bringing duplicative or weak product liability cases to court.
SourcesS. Horowitz: Israel's Supreme Court Signals a Shift on Class Action Costs (opens in new tab)

Unlock the full brief

Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.